June 7, 2019 / 6:31 AM / 20 days ago

BRIEF-Orphazyme Prepares To File Acrimoclomol In Europe For Niemann-Pick Disease Type C

June 7 (Reuters) - Orphazyme A/S:

* CONFIRMS ITS INTENTION TO FILE THE MARKETING AUTHORIZATION APPLICATION FOR NIEMANN-PICK DISEASE TYPE C IN H1 2020

* ADDITIONAL DATA, INCLUDING 12-MONTH OPEN-LABEL EXTENSION DATA, WILL BECOME AVAILABLE DURING H2 2019 AND MUST BE INCLUDED IN THE MAA

* ORPHAZYME PLANS TO MEET WITH THE US FOOD AND DRUG ADMINISTRATION (FDA) TO DISCUSS THE PATHWAY FORWARD DURING THE SUMMER

Source text for Eikon:

Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below